DBS Initiates AbbVie(ABBV.US) With Hold Rating
Maintaining a Hold: Balancing AbbVie's Strategic Successes Against Market Challenges
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $218
Positive Outlook for AbbVie: Buy Rating Affirmed Amid Strong Aesthetics Sales and Market Share Stability
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating
AbbVie Price Target Raised to $209.00/Share From $196.00 by Piper Sandler
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $209
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
AbbVie Analyst Ratings
Morgan Stanley Adjusts Price Target on AbbVie to $218 From $211, Maintains Overweight Rating
AbbVie Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
Daiwa Adjusts Price Target on AbbVie to $190 From $171
HSBC Adjusts Price Target on AbbVie to $215 From $185
Evercore Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $192
BNP Paribas Exane Adjusts Price Target on AbbVie to $193 From $172
Evercore ISI Sticks to Its Buy Rating for AbbVie (ABBV)
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), AbbVie (ABBV)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)